Last updated on July 2019

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST


Brief description of study

This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120 subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 mg or matching placebo orally (PO) 3 times daily (TID) in combination with best supportive care.

Clinical Study Identifier: NCT02847429

Find a site near you

Start Over

Centre Oscar Lambret

Lille, France
3.84miles
  Connect »